Nymox Pharmaceutical is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia and the treatment of low-grade localized prostate cancer. Co. has developed and markets NicAlert and TobacAlert, which are test strips for determining whether a person is using tobacco products (NicAlert) or has been exposed to second-hand smoke (TobacAlert). Both NicAlert and TobacAlert employ the patented technology of Co.'s subsidiary, Serex, Inc., to provide a read-out of levels of cotinine, a by-product of the body's breakdown of nicotine and generally regarded as the indicator of tobacco exposure for smokers and nonsmokers. The NYMX stock yearly return is shown above.
The yearly return on the NYMX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NYMX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|